We recently published a list of Top 20 Falling Stocks with Unusual Volume. In this article, we are going to take a look at where agilon health, inc. (NYSE:AGL) stands against other top falling stocks with unusual volume.
Uncertainty around tariffs and macroeconomic conditions has dented investor confidence, resulting in stock prices falling. While some stocks have come under pressure due to the above two reasons, others have simply followed the market direction or have dipped for company-specific reasons.
Regardless of the reasons for stocks going down, falling stocks provide an opportunity for fresh investors to get in at good prices. Once the risks subside, these stocks usually recover quickly as well. We decided to uncover these stocks and see if it makes sense to put money in them to take advantage of the ongoing market turmoil.
To come up with our list of top 20 stocks falling with unusual volume, we looked at stocks over $300 million in market cap, their one-week performance, and used relative volume to detect the unusual volume activity.
Relative volume compares the daily volume to the three-month average trading volume of the stock, making it easy to detect spikes in volume. These spikes usually signal something important is happening, which, when combined with falling prices, becomes a red flag that investors can’t ignore.
A doctor in scrubs interacting with a Medicare Advantage member in her home.
agilon health, inc. (NYSE:AGL) operates as a healthcare services provider for seniors. The company provides a platform that manages patients’ comprehensive healthcare needs through a subscription-based model. The company’s stock is down 27.27% in a week on a relative volume of 3.84.
All was going well when the healthcare provider received an upgrade at the start of this year. Citi’s analyst Daniel Grosslight upgraded the stock from Sell to Neutral on the back of its 2025 outlook for the U.S. Health Tech and Distribution space. Grosslight raised his price target from $1.75 to $2.25. Driven by a favorable Medicare Advantage market outlook, he believes that there is limited downside potential.
Analyst Daniel Grosslight highlighted:
“We do think there is potential that a Trump administration and CMS (likely led by Dr. Mehmet Oz) implement more Medicare Advantage-favorable policies.”
After the upgrade, the stock took off, nearly tripling in value before it crashed on high volume last week. The trigger was a downgrade by Baird, citing a lack of financial backing for the senior care sector. The firm believes that tough macroeconomic conditions, coupled with policy issues, will keep the medium-term earnings muted. The market has been re-rating the stock since, and it would be a good idea to let the dust settle before taking a position in the stock.
